Legal & General Group Plc raised its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 14.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 70,576 shares of the company’s stock after buying an additional 8,653 shares during the quarter. Legal & General Group Plc’s holdings in Ionis Pharmaceuticals were worth $3,816,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of IONS. Two Sigma Advisers LP increased its holdings in Ionis Pharmaceuticals by 96.9% in the fourth quarter. Two Sigma Advisers LP now owns 606,911 shares of the company’s stock valued at $32,810,000 after buying an additional 298,700 shares in the last quarter. D. E. Shaw & Co. Inc. grew its position in shares of Ionis Pharmaceuticals by 252.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 410,699 shares of the company’s stock valued at $22,202,000 after purchasing an additional 294,184 shares during the last quarter. BlackRock Inc. grew its position in shares of Ionis Pharmaceuticals by 2.9% in the fourth quarter. BlackRock Inc. now owns 7,676,257 shares of the company’s stock valued at $414,977,000 after purchasing an additional 213,000 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Ionis Pharmaceuticals by 34.8% in the fourth quarter. Two Sigma Investments LP now owns 727,545 shares of the company’s stock valued at $39,331,000 after purchasing an additional 187,876 shares during the last quarter. Finally, Vanguard Group Inc grew its position in shares of Ionis Pharmaceuticals by 1.4% in the third quarter. Vanguard Group Inc now owns 11,091,298 shares of the company’s stock valued at $572,089,000 after purchasing an additional 157,770 shares during the last quarter. 85.05% of the stock is owned by institutional investors.
In related news, SVP Patrick R. O’neil sold 19,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $59.25, for a total transaction of $1,161,300.00. Following the sale, the senior vice president now owns 23,673 shares in the company, valued at $1,402,625.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Richard S. Geary sold 46,240 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $84.01, for a total transaction of $3,884,622.40. Following the sale, the senior vice president now owns 45,442 shares in the company, valued at approximately $3,817,582.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 339,205 shares of company stock worth $24,034,607. 2.44% of the stock is owned by company insiders.
IONS stock opened at $84.61 on Friday. Ionis Pharmaceuticals Inc has a 12 month low of $39.07 and a 12 month high of $86.58. The company has a market capitalization of $11.59 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 256.41 and a beta of 2.42. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $2.20. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. The firm had revenue of $192.00 million for the quarter, compared to analyst estimates of $159.59 million. During the same quarter last year, the business earned ($0.03) earnings per share. Ionis Pharmaceuticals’s revenue was up 14.3% compared to the same quarter last year. Equities analysts anticipate that Ionis Pharmaceuticals Inc will post 0.02 EPS for the current fiscal year.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Read More: What Are Treasury Bonds?
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.